Is bmrn a good investment

**BioMarin Pharmaceutical (BMRN) appears to be a good investment**, based on the following points:

1. **Analyst Ratings and Price Targets**: BMRN has an average price target of $108.05, with a "Buy" consensus rating. This suggests that analysts are optimistic about the stock's future performance.
2. **Recent Developments**: BioMarin has presented new Phase 3 data that demonstrate the long-term safety and efficacy of ROCTAVIAN, which is a significant milestone for the company. This positive data could lead to increased investor confidence.
3. **Market Potential**: The market for drugs targeting rare diseases, like BioMarin's ROCTAVIAN, is expected to grow significantly in the coming years. This growth could provide opportunities for BioMarin to increase its market share and profitability.
4. **Institutional Ownership**: Several institutional investors, including Frontier Capital Management Co. LLC, have significantly invested in BioMarin, indicating confidence in the company's future prospects.
5. **Financial Health**: BioMarin has a strong balance sheet, with significant cash reserves and no debt, which provides financial flexibility and stability.

In conclusion, the analyst ratings, recent developments, market potential, institutional ownership, and financial health of BioMarin Pharmaceutical suggest that it is a good investment option. However, as with any investment, it's important to consider your own risk tolerance and investment strategy before making a decision.